Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenx	$580.95 +0.8%	$587.69	$359.37 ▼ $678.21	$35.47B	0.57	323,585 shs	171,708 shs
BNTX BioNTech	$100.25 +2.8%	$97.48	$76.53 ▼ $131.49	$24.10B	1.35	918,761 shs	559,039 shs
TAK Takeda Pharmaceutical	$14.79 +1.4%	$14.66	$12.58 ▼ $15.43	$47.06B	0.26	1.94 million shs	2.50 million shs
TEVA Teva Pharmaceutical Industries	$17.58 -3.1%	$15.49	$12.47 ▼ $22.80	$19.94B	0.62	10.06 million shs	13.10 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenx	-0.61%	-1.49%	-7.20%	-7.76%	+57.30%
BNTX BioNTech	-1.04%	-1.57%	-6.22%	-10.36%	+3.65%
TAK Takeda Pharmaceutical	-0.61%	+1.85%	-3.82%	+1.71%	+11.25%
TEVA Teva Pharmaceutical Industries	+2.31%	+9.38%	+20.63%	+11.08%	+8.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenx	3.2413 of 5 stars	3.5	2.0	0.0	3.5	1.7	1.9
BNTX BioNTech	2.6307 of 5 stars	4.4	2.0	0.0	3.1	0.8	0.0
TAK Takeda Pharmaceutical	2.7469 of 5 stars	0.0	3.0	2.5	3.3	0.0	2.5
TEVA Teva Pharmaceutical Industries	2.6156 of 5 stars	3.6	3.0	0.8	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenx	3.05	Buy	$709.18	22.07% Upside
BNTX BioNTech	2.83	Moderate Buy	$140.14	39.79% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.50	39.33% Upside

Current Analyst Ratings Breakdown

Latest TEVA, TAK, ARGX, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/21/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $134.00
5/14/2025	ARGX argenx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$699.00
5/14/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/13/2025	ARGX argenx	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/13/2025	ARGX argenx	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$680.00 ➝ $680.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenx	$2.58B	13.75	N/A	N/A	$69.22 per share	8.39
BNTX BioNTech	$2.75B	8.78	$4.31 per share	23.25	$92.17 per share	1.09
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.46 per share	4.27	$15.39 per share	0.96
TEVA Teva Pharmaceutical Industries	$16.62B	1.20	$3.48 per share	5.05	$4.75 per share	3.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenx	-$295.05M	$16.21	N/A	53.54	N/A	-2.11%	-1.45%	-1.29%	7/24/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.40	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	8/4/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.22	36.98	8.96	0.24	4.53%	9.39%	4.53%	7/30/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.69	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest TEVA, TAK, ARGX, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ARGX argenx	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenx	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.53%	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.58%	-8.36%	240.91%	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.75%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenx	N/A	8.53	7.88
BNTX BioNTech	0.01	7.33	7.21
TAK Takeda Pharmaceutical	0.63	1.31	0.72
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenx	60.32%
BNTX BioNTech	15.52%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ARGX argenx	2.43%
BNTX BioNTech	19.20%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenx	650	61.06 million	59.29 million	Optionable
BNTX BioNTech	3,080	240.39 million	193.71 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

TEVA, TAK, ARGX, and BNTX Headlines

Recent News About These Companies

Teva gives aggressive guidance for innovative drugs

May 29 at 4:24 PM | en.globes.co.il

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

May 29 at 4:24 PM | msn.com

Truist Securities Initiates Coverage of Teva Pharmaceutical Industries Limited - Depositary Receipt () (TEVA) with Buy Recommendation

May 29 at 11:23 AM | msn.com

Teva Reaffirms 2027 Targets, Aims for 30% Operating Margin

May 29 at 11:23 AM | msn.com

Teva Pharmaceutical Industries (NYSE:TEVA) Earns Buy Rating from Analysts at Truist Financial

May 29 at 10:06 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. Announces Acceleration Plan to Transform into a Leading Biopharma Company by 2030

May 29 at 8:32 AM | quiverquant.com

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 29 at 8:00 AM | globenewswire.com

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

May 28 at 12:11 PM | zacks.com

FDA fast-tracks Teva's coeliac disease treatment

May 28 at 8:33 AM | pharmaphorum.com

Capital A Wealth Management LLC Invests $596,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 28 at 6:26 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

May 27 at 9:28 PM | insidermonkey.com

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27 at 5:30 PM | globenewswire.com

Teva initiated with bullish view at Truist, here's why

May 27 at 4:33 PM | https://thefly.com

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27 at 4:30 PM | globenewswire.com

Why Is Teva Stock Trading Higher On Tuesday?

May 27 at 3:44 PM | benzinga.com

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

May 27 at 12:21 PM | zacks.com

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 27 at 8:30 AM | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 36,454 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 27 at 4:46 AM | marketbeat.com

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

May 26 at 10:13 AM | finance.yahoo.com

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

May 26 at 10:13 AM | insidermonkey.com

Royal Bank of Canada Increases Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 26 at 4:07 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?
By Leo Miller | May 20, 2025
View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?
5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears
By Thomas Hughes | May 14, 2025
View 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears
Is Intel Stock a Bargain or a Burden? Cheap Stock, High Stakes
By Jeffrey Neal Johnson | May 7, 2025
View Is Intel Stock a Bargain or a Burden? Cheap Stock, High Stakes
Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
By Nathan Reiff | May 10, 2025
View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
Don’t Take Dick’s Sporting Goods Seriously? Big Mistake
By Thomas Hughes | May 29, 2025
View Don’t Take Dick’s Sporting Goods Seriously? Big Mistake

TEVA, TAK, ARGX, and BNTX Company Descriptions

argenx NASDAQ:ARGX

$580.95 +4.71 (+0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$581.08 +0.13 (+0.02%)

As of 04:04 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$100.25 +2.72 (+2.79%)

Closing price 04:00 PM Eastern

Extended Trading

$98.99 -1.26 (-1.26%)

As of 07:53 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Takeda Pharmaceutical NYSE:TAK

$14.79 +0.20 (+1.37%)

Closing price 03:59 PM Eastern

Extended Trading

$14.70 -0.09 (-0.61%)

As of 04:34 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$17.58 -0.57 (-3.12%)

Closing price 03:59 PM Eastern

Extended Trading

$17.60 +0.01 (+0.06%)

As of 07:56 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time